Latest news with #Stelo
Yahoo
16-05-2025
- Business
- Yahoo
DXCM Q1 Earnings Call: Coverage Expansion and Product Pipeline Shape 2025 Outlook
Medical device company DexCom (NASDAQ:DXCM) beat Wall Street's revenue expectations in Q1 CY2025, with sales up 12.5% year on year to $1.04 billion. The company expects the full year's revenue to be around $4.6 billion, close to analysts' estimates. Its non-GAAP profit of $0.32 per share was in line with analysts' consensus estimates. Is now the time to buy DXCM? Find out in our full research report (it's free). Revenue: $1.04 billion vs analyst estimates of $1.02 billion (12.5% year-on-year growth, 1.8% beat) Adjusted EPS: $0.32 vs analyst estimates of $0.33 (in line) Adjusted EBITDA: $230.4 million vs analyst estimates of $251.9 million (22.2% margin, 8.5% miss) The company reconfirmed its revenue guidance for the full year of $4.6 billion at the midpoint Operating Margin: 12.9%, up from 11% in the same quarter last year Free Cash Flow Margin: 9.3%, down from 16.5% in the same quarter last year Organic Revenue rose 13.8% year on year (24.8% in the same quarter last year) Market Capitalization: $33.93 billion DexCom's first quarter results reflected ongoing momentum in its core continuous glucose monitoring (CGM) business, with management attributing growth to expanded commercial reach, increased patient starts—particularly among type 2 non-insulin users—and new product enhancements. CEO Kevin Sayer cited record levels of new customer acquisition, driven by broadened prescriber activity and new payer access wins, as well as the recent launch of Stelo, DexCom's over-the-counter biosensor, and updates to the G7 platform. Looking forward, management underscored the importance of continued payer coverage expansion, particularly with all three major pharmacy benefit managers (PBMs) now committed to covering DexCom's G7 for wider patient populations. CFO Jereme Sylvain emphasized the company's focus on managing supply chain costs and margin pressures, while maintaining investment in product innovation and operational efficiency. Sayer stated, 'We believe we can continue to demonstrate our value time and time again,' highlighting DexCom's efforts to secure broader access, data-driven outcomes, and regulatory clearances. DexCom's management provided detailed context on the drivers of first quarter performance and addressed several business-critical developments impacting the outlook for 2025. Type 2 Diabetes Access Gains: Management emphasized that recent wins with large PBMs have accelerated adoption among type 2 non-insulin users. The company saw a notable uptick in new patient starts from this population, which is now a material portion of overall new additions. Stelo Launch and Uptake: The over-the-counter Stelo sensor, targeting type 2 diabetes, prediabetes, and wellness users, continues to attract new customers. Stelo's app enhancements and expanded distribution, including availability on Amazon, have driven over 200,000 downloads to date. 15-Day G7 System Clearance: DexCom secured FDA approval for a 15-day wear G7 sensor, increasing convenience and potentially improving margins. The product is slated for launch in the second half of the year, with work underway to ensure compatibility with insulin pumps and payer coverage. Operational and Supply Dynamics: The company navigated short-term supply constraints by expediting shipments and working closely with distribution partners. Management acknowledged incremental freight costs but confirmed that manufacturing output and product quality have stabilized. FDA Warning Letter Response: DexCom addressed an FDA warning letter received in March, implementing corrective process controls without impacting new product approvals or ongoing distribution. Management expects to resolve outstanding issues while continuing to prioritize innovation. Management's outlook for 2025 centers on broadening access for DexCom's CGM products, scaling adoption among type 2 diabetes patients, and improving operational efficiency amid cost pressures. Broader Payer Coverage: Coverage expansion among major PBMs is expected to drive growth in the type 2 non-insulin segment, unlocking a larger addressable market and supporting continued high rates of new patient acquisition. Product Pipeline Execution: The upcoming launch of the 15-day G7 sensor and ongoing software enhancements—such as Stelo app updates and integration with third-party wellness platforms—are positioned to support retention, differentiation, and margin improvement over time. Margin Management and Cost Controls: Management highlighted ongoing programs to offset elevated freight costs and inflationary pressures, including leveraging prior investments in automation, AI, and sales force expansion. The ability to balance investment with efficiency is seen as key to maintaining operating margins despite external headwinds. Matt Taylor (Jefferies): Asked about the closure of the gap between volume and revenue growth. Management confirmed inventory normalization and record new patient starts, indicating that volume growth remains robust and consistent with earlier trends. Larry Biegelsen (Wells Fargo): Questioned why full-year guidance was unchanged despite strong Q1 organic growth. CFO Jereme Sylvain said it was too early to adjust guidance after one quarter, emphasizing a commitment to deliver on full-year targets. Danielle Antalffy (UBS): Sought insight on DexCom's resilience in a potential recession. Management cited strong payer coverage and the cost-saving value of CGM to health systems, expressing confidence in the company's positioning relative to peers. Jeff Johnson (Baird): Inquired about gross margin cadence and whether manufacturing issues persisted. Management stated margin improvement is expected later in the year and indicated that manufacturing output and quality are on track, with no ongoing process issues. Jayson Bedford (Raymond James): Probed on international revenue softness and supply dynamics. Management noted localized strength in Japan and France but acknowledged timing variability in international coverage wins, resulting in some quarterly choppiness. Looking ahead, the StockStory team will monitor (1) execution of the 15-day G7 system launch and its adoption rates, (2) continued expansion of coverage for type 2 non-insulin diabetes patients among payers, and (3) the pace at which supply chain costs normalize and margins recover. Additional signposts include data readouts from the type 2 diabetes randomized controlled trial and further growth in Stelo's user base. DexCom currently trades at a forward P/E ratio of 40×. Is the company at an inflection point that warrants a buy or sell? The answer lies in our free research report. Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Miami Herald
07-05-2025
- Health
- Miami Herald
Oura launches genius features to take on Apple, Fitbit, and Whoop
Business Oura launches genius features to take on Apple, Fitbit, and Whoop Tracking your steps and sleep used to be enough. But as consumers grow more health-conscious and tech-savvy, the bar is higher than ever for wearables. People want real health insights, not just data dumps. They want to know how their body responds to food, stress, rest, and movement in real time. Related: Lululemon fixes an embarrassing problem I know because I'm one of them. I've worn every tracker out there - Apple Watch, Fitbit - and while they're useful, I always felt like something was missing. I wanted more than passive data. I wanted a tool that could help me understand my patterns, not just track them. And increasingly, people like me want it all without a screen strapped to their wrist - something that blends seamlessly into daily life, not clashes with it. (Because let's be honest, a chunky watch doesn't always vibe with a carefully styled outfit.) That's exactly the gap one major wearable company is aiming to fill. Oura's two new features are game-changers. Image source: Oura Oura bets big on AI technology Oura, the company behind the popular smart ring, just announced two major new features designed to deepen its role in metabolic health: Meals and Glucose. Both tools rely on AI and personalized pattern recognition to offer users a more holistic view of their health. The Meals feature is wild - you literally just take a picture of your food, and the ring uses AI to figure out when you've eaten. No logging, no typing, no swiping through food databases. It just knows. I tested this feature when it was in Oura Labs and was obsessed. It just worked. When I got the notification that it was going away, I was genuinely bummed, so seeing it return now in an official way is a big win. Related: Forget Apple Watch and Fitbit - try these AI smart shirts instead For the Glucose feature, Oura teamed up with Dexcom to bring real-time blood sugar tracking into the mix. Users can now buy a Stelo - a tiny sensor you wear on your upper arm - directly from Oura's website. It tracks glucose 24/7 and syncs with the ring to show how your daily habits affect your levels. So, in other words, this ring might understand your habits better than any other smart device you've ever worn. "Our product roadmap for this year is built on a robust investment in AI-forward offerings that enable a deeper understanding of the dynamic interplay of key health factors," said Chief Product Officer Holly Shelton in Oura's latest press release. Oura is a growing threat to Apple and Fitbit While Apple and Fitbit have dominated the wrist-wearable space for over a decade, they're increasingly facing pressure from more niche - and now, more innovative - competitors. Oura's ring offers a form factor that many users prefer for 24/7 wear, especially while sleeping. But now, it's also pushing the boundaries of what a wellness device can track. Apple's been teasing non-invasive glucose tracking for years - still nothing. And Whoop? No glucose tools, period. Oura just leapfrogged them both - not by building a glucose sensor, but by integrating with Dexcom and building smarter health correlations around the data. And let's not forget the out-of-this-world meal detection tool. Just snapping a photo of your lunch and having your ring know what you ate? That's the kind of futuristic simplicity users crave - and something Oura's competition hasn't even touched. This move also signals a broader trend: wellness wearables inching closer to medical-grade insights, without going full clinical. For users, it's a win. For competitors, it's a wake-up call. Related: Veteran fund manager unveils eye-popping S&P 500 forecast The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc. This story was originally published May 7, 2025 at 4:00 PM.
Yahoo
06-05-2025
- Health
- Yahoo
ŌURA rolls out glucose app linked with Dexcom's CGM Stelo
ŌURA has signalled an entry into the consumer diabetes space, offering a new glucose feature for its ring that uses insights from Dexcom's over-the-counter (OTC) continuous glucose monitor (CGM) Stelo. The integration between the Oura smart ring and Stelo is the culmination of a partnership between ŌURA and Dexcom in November 2024. The diabetes device giant invested $75m into Finland-based ŌURA to enable data flow between their respective products. The Glucose feature on the Oura app will show daily glucose readings set against periods of meals, sleep, stress, and activity. Data will be extracted from Stelo, the first biosensor approved by the US Food and Drug Administration (FDA) for use without a prescription. Oura will also provide insights to users on how glucose interacts with meals, stress, and daily movement. This, the ring developer says, will help patients learn lifestyle habits that help them maintain or achieve optimal glucose levels. 'Personalised guidance and insights are essential for helping people understand how their lifestyle choices affect their body, while also encouraging them to make informed health decisions that can improve their overall quality of life,' said Jake Leach, executive vice-president and chief operating officer at Dexcom. The glucose feature was launched alongside Meals, an AI-powered tool that provides nutrition information from photographs of food. When launched, Meals and Glucose will be available on iOS and Android for US-based Oura users, with plans to launch Meals internationally later this year. The partnership between ŌURA and Dexcom has signalled a new chapter in the consumer health and medical device sector convergence. ŌURA is fast becoming a household name in the wearable technology sector, thanks to its smart ring. The device measures sleep, stress, and cardiovascular data, among others. It spurred the company to nearly double its annual sales in 2024 to reach around $500m, with 2.5 million rings sold worldwide. Dexcom, meanwhile, is a significant player in the diabetes medical device market, occupying around 74% of the CGM market share in the US, according to analysis by GlobalData. Experts have previously said the partnership between the two companies has the potential to improve adherence and behaviour changes, both critical for long-term diabetes management. One of the key financial aspects of the partnership was that both Dexcom and ŌURA would co-market and cross-sell each other's products. That is indeed now a reality, with new and existing Oura members able to purchase Stelo directly from the smart ring developer for $99. The CGM can be bundled with or without a ring, representing a model example of consumer health and medtech product combination, though this is currently only available in the US.
Digital Trends
06-05-2025
- Health
- Digital Trends
Latest Oura Ring features focus on metabolic health improvement
The Oura Ring 4 is rapidly becoming the center piece of your efforts to lead a healthier life, and the introduction of two new features designed to improve metabolic health back this up. The app now has an AI-powered food tracking feature called Meals, and integration with the Dexcom Stelo, the first glucose monitor available in the U.S. with Food and Drug Administration (FDA) approval and without a prescription. The Meals feature has been part of Oura Labs, the brand's space for beta testing features, for a while and has now been elevated to become a permanent fixture in the app. It's a more advanced, less calorie-focused way of tracking your meals, which provides more information on how food may be affecting your health and wellbeing. It works by analyzing a photo of your meal, and examines the key nutritional elements within, before providing guidance on how to meet your goals. Recommended Videos Crucially, Oura emphasizes how Meals won't penalize your food choices, and won't judge based on what it 'sees' in the photo. Like Oura's decision to optionally minimize calorie burn as a goal, the focus on making better food choices through less aggressive methods to meet the personal goals specified in the app should help more people try the feature out. The data from the Meals feature works with the integration of Dexcom's Stelo wearable to give Oura wearers greater insight into their metabolic health. Stelo is used worn on your upper arm and provides data on glucose levels, which is then integrated into the Oura Ring app. Dexcom's chief operating officer Jake Leach explains why it's a great pairing: 'Personalized guidance and insights are essential for helping people understand how their lifestyle choices affect their body, while also encouraging them to make informed health decisions that can improve their overall quality of life. By integrating with Oura, we're bringing the first glucose biosensor and smart ring integration to the market, providing a one-of-a-kind and personalized metabolic health experience that allows users to better understand the link between activity, sleep, stress, nutrition, and their glucose.' Oura's vice president of science Shyamal Patel continued: 'Meal-induced glucose spikes can vary significantly due to factors like sleep, stress, exercise, and meal timing, which is why it's important to approach metabolic health holistically rather than focusing exclusively on diet. Instead of avoiding specific foods based on one spike, we encourage members to observe patterns, experiment with habits, and discover what helps them maintain better glucose balance over time. With this approach, members can maintain a healthy relationship with food while building long-term habits that support metabolic health.' Both the Meals and Glucose features are available in the Oura Ring app in the U.S. now, with Meals expected to launch internationally later in 2025. Dexcom's Stelo wearable is only available in the U.S. and will be available through Oura's website for $99, and can be purchased with an Oura Ring as a bundle. However, this only provides Stelo biosensors for a single month of tracking, and it costs a further $99 every month afterwards. This is on top of the Oura Ring's $6 per month subscription to view most of the data in its app. Please enable Javascript to view this content
Yahoo
02-05-2025
- Business
- Yahoo
DexCom Inc (DXCM) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Supply Challenges
Worldwide Revenue: $1.036 billion, up 12% reported and 14% organic growth compared to Q1 2024. US Revenue: $751 million, a 15% increase from Q1 2024. International Revenue: $286 million, 7% growth reported and 12% organic growth. Gross Profit: $596.2 million, 57.5% of revenue, down from 61.8% in Q1 2024. Operating Expenses: $455.3 million for Q1 2025. Operating Income: $143.1 million, 13.8% of revenue, compared to $140.2 million, 15.2% of revenue in Q1 2024. Adjusted EBITDA: $230.4 million, 22.2% of revenue, compared to 24% in Q1 2024. Net Income: $127.7 million or $0.32 per share. Cash and Cash Equivalents: Approximately $2.7 billion. Share Repurchase Program: Announced $750 million share repurchase program. Full-Year Revenue Guidance: Reaffirmed at $4.6 billion, 14% growth. Full-Year Gross Profit Margin Guidance: Reduced to approximately 62%. Full-Year Operating Margin and Adjusted EBITDA Margin Guidance: Reaffirmed at approximately 21% and 30%, respectively. Warning! GuruFocus has detected 3 Warning Signs with DXCM. Release Date: May 01, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. DexCom Inc (NASDAQ:DXCM) reported a 14% organic revenue growth in Q1 2025 compared to Q1 2024, marking the second consecutive quarter of reaccelerating revenue growth. The company successfully navigated short-term supply dynamics while maintaining strong demand in the US market, ensuring limited customer disruption. DexCom Inc (NASDAQ:DXCM) expanded its commercial reach, leading to record levels of new customer starts, particularly from the type 2 non-insulin population. The introduction of Stelo, the first over-the-counter CGM, and broader coverage within the type 2 market have been well-received, enhancing customer experience. DexCom Inc (NASDAQ:DXCM) announced a $750 million share repurchase program, reflecting confidence in its strong revenue and cash flow growth outlook. DexCom Inc (NASDAQ:DXCM) received a warning letter from the FDA related to observations at its San Diego and Mesa facilities, requiring corrective actions. The company's gross profit margin decreased to 57.5% in Q1 2025 from 61.8% in Q1 2024, impacted by supply chain issues and increased freight costs. Despite strong Q1 performance, DexCom Inc (NASDAQ:DXCM) maintained its full-year revenue guidance, indicating caution about future quarters. The international revenue growth was below expectations, with some choppiness due to the timing of coverage wins and supply dynamics. DexCom Inc (NASDAQ:DXCM) faces ongoing inflationary pressures and potential tariff impacts, which could affect global manufacturing costs. Q: Can you discuss the impact of supply dynamics on US revenue growth and the gap between volume and revenue growth? A: Jereme Sylvain, CFO, explained that they exited the quarter with normalized supply levels, which required significant effort. Despite this, they achieved a record new patient quarter, indicating strong performance. The volume growth aligns with a 25% patient increase, consistent with previous trends, and the price-volume gap is closing as expected. Q: Why did you maintain full-year guidance despite 14% organic growth in Q1, and how does the 15 Day launch affect gross margin guidance? A: Jereme Sylvain, CFO, stated that it's early in the year, and they want to see how the year unfolds before adjusting guidance. The 15 Day launch was included in the original guidance, and its impact on gross margin is expected to be small initially, as it will ramp up over time. Q: What trends are you seeing in type 2 non-insulin and basal patient utilization and retention? A: Kevin Sayer, CEO, noted strong retention rates in these populations, particularly with reimbursement. Stelo users are also reordering regularly. Jereme Sylvain added that utilization remains strong in covered markets, and Stelo is seeing good uptake among type 2 users. Q: How exposed is DexCom to a potential recession, and how did you analyze this risk? A: Jereme Sylvain, CFO, explained that they've analyzed their exposure to coverage levels and economic conditions. DexCom's products save costs and are integral to care patterns, positioning them well to weather economic downturns. Kevin Sayer emphasized their value in providing cost-effective health solutions. Q: Can you provide more details on the international revenue performance and any supply chain impacts? A: Jereme Sylvain, CFO, highlighted pockets of strength in France and Japan due to coverage expansions. While there is some choppiness in international business due to timing of coverage wins, underlying volume demand remains strong. Supply dynamics did not significantly impact international revenue. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
